Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Last revisionBoth sides next revision
serum_biomarkers_for_neurodegeneration [2019/12/11 23:32] – adminserum_biomarkers_for_neurodegeneration [2019/12/19 23:47] – [Data] admin
Line 3: Line 3:
 ===== Objectives ===== ===== Objectives =====
  
-Identify novel serum biomarkers for neurodegeneration that allow accurate diagnosis of Alzheimer's disease (AD) in Hispanic and non-Hispanic white populations.+Identify novel serum biomarkers for neurodegeneration that allow accurate diagnosis of Alzheimer's disease (AD) in Hispanic and non-Hispanic white populations (Specific {{:analysis_plan.docx|Aims}} ).
  
 ===== Data ===== ===== Data =====
  
-  - DNA methylation data of [[29 subjects|]] were measured in 2019 using Infinium [[https://support.illumina.com/downloads/infinium-methylationepic-v1-0-product-files.html|MethylationEpic]] V1 Array. PBMC samples were collected before and after Rapamycin (16 subjects) and placebo (13 subjects) treatment for 6-8 weeks.+  - Six proteins were measured in blood samples of ~1200 Hispanic and ~500 non-Hispanic white participants. Covariates include gender, education, and age. 
 +  - The cognitive status of participants were assessed in several visits over years. The number of visits and time intervals between visits vary across participants. 
  
 ===== Collaborators ===== ===== Collaborators =====
  
-Dr. [[https://wp.uthscsa.edu/mimg/team-member/ellen-kraig-ph-d/|Ellen Kraig]], an immunologist, and Dr. [[https://www.uthscsa.edu/academics/biomedical-sciences/faculty/profile/0V71EU5IM/Kellogg,-Dean-L.-Jr.|Dean Kellogg]], a physiologist, both from the University of Texas Health Science Center at San Antonio.+Dr. Sudha [[https://www.uthscsa.edu/academics/biomedical-sciences/faculty/profile/53266/Seshadri,-Sudha|Seshadri]], the Founding director of the Glenn [[https://biggsinstitute.org/|Biggs]] Institute for Alzheimer's & Neurodegenerative Diseases, and Dr. Mitzi [[https://biggsinstitute.org/team-member/mitzi-m-gonzales-ph-d/|Gonzales]] from the Department of Neurology at University of Texas Health Science Center in San Antonio. This study is supported by Texas Alzheimer's Research and Care Consortium (TARCC). 
 + 
 + 
 +===== Analysis =====
  
-===== DNA methylation analysis =====+  - Linear models. 
 +  - Regularized regression, e.g., the LASSO. 
 +  - Hidden Markov Models (HMM).
  
-We follow the Bioconductor [[https://www.bioconductor.org/packages/release/workflows/vignettes/methylationArrayAnalysis/inst/doc/methylationArrayAnalysis.html#differential-methylation-analysis|workflow]] to identify the probes and regions that are differentially methylation due to Rapamycin treatment. 
  
 ===== Related work ===== ===== Related work =====
  
-  - Kraig, Ellen, et al. "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects." [[https://www.sciencedirect.com/science/article/pii/S0531556517309130|Experimental gerontology]] 105 (2018): 53-69.+  - Eagan, Danielle E., et al. "Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults." Cardiovascular psychiatry and neurology 2012 ([[https://www.hindawi.com/journals/cpn/2012/120540/|2012]]).